The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Accelerating sustainability in Indian pharma industry
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Nadda also interacted with senior officials of the Union Health Ministry after taking charge where he was briefed about the ongoing projects
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Subscribe To Our Newsletter & Stay Updated
